Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise

Denali Therapeutics

06/08/2026 21:09

Overview
Biotechnology firm's first full qtr AVLAYAH sales generated $3.6 mln in net product revenue
Net loss for Q2 widened slightly yr/yr as launch expenses increased
Company received $195 mln from Priority Review Voucher sale, boosting pro forma cash above $1.1 bln

Outlook
Denali projects third-quarter AVLAYAH net product revenue of $10.0 mln to $12.0 mln
Company says initial AVLAYAH demand is tracking ahead of internal expectations
Denali notes rapid expansion of commercial access for AVLAYAH

Result Drivers
AVLAYAH LAUNCH - First full qtr of AVLAYAH commercial sales generated $3.6 mln in net product revenue, supported by positive engagement from patients, caregivers and physicians, and rapid expansion of payer coverage
LAUNCH-RELATED COSTS - Higher selling, general and administrative expenses were primarily driven by increased headcount to support the AVLAYAH launch
LOWER MANUFACTURING COSTS - Cost of goods sold was low as manufacturing costs incurred prior to FDA approval were previously expensed to R&D

Company press release: ID:nGNX3nyzJz

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$127.55 mln
 
Q2 Loss Per Basic Share
 
$0.68
 
Q2 Operating Expenses
 
$134.15 mln
 
Q2 Operating Income
 
-$130.54 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Denali Therapeutics Inc. is $35.00, about 43.3% above its August 5 closing price of $24.42

Reuters Recommended Reads
Aug 6 - Viridian Therapeutics Q2 net loss widens as Lumvoa launch lifts costs
Aug 5 - Biopharma firm MannKind Q2 posts net loss on product launch expenses
Aug 3 - Crinetics Q2 revenue jumps on PALSONIFY launch, withdraws guidance

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)